Cập nhật về Coronavirus (COVID-19): FDA cho phép sử dụng kết hợp thuốc để điều trị COVID-19
Today, the FDA issued an emergency use authorization for the drug baricitinib, in combination wi…
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
文章相關商品
系統已根據文章標題、摘要和正文，自動匹配目前在售的強相關藥品。
巴瑞克替尼片 BARUDX Baricitinib
巴瑞替尼（Baricitinib）是一種每日口服1次的選擇性、可逆性JAK1和JAK2抑制劑，目前臨床開發用於多種發炎性疾病和自體免疫疾病的治療，包括類風濕性關節炎（RA）、僵直性脊椎炎（AS）、乾癬、異位性皮膚炎、系統性紅斑狼、潰瘍性腸斑狼、潰瘍性腸斑症(UC)、潰瘍性腸斑狼、潰瘍性腸斑。
查看商品
巴瑞克替尼片 BARUDX Baricitinib
巴瑞替尼（Baricitinib）是一種每日口服1次的選擇性、可逆性JAK1和JAK2抑制劑，目前臨床開發用於多種發炎性疾病和自體免疫疾病的治療，包括類風濕性關節炎（RA）、僵直性脊椎炎（AS）、乾癬、異位性皮膚炎、系統性紅斑狼、潰瘍性腸斑狼、潰瘍性腸斑症(UC)、潰瘍性腸斑狼、潰瘍性腸斑。
查看商品
常見問題
Which products are related to this article?
The system matched these relevant products from the article content: 盧修斯 巴瑞克替尼 Baricitinib 線上購買、巴瑞克替尼片 BARUDX Baricitinib、巴瑞克替尼片 BARUDX Baricitinib.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
